NCT06991738 NOT YET RECRUITING 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT04927416 RECRUITING The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03841617 RECRUITING The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT06239194 RECRUITING Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06814496 RECRUITING Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06959511 RECRUITING Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
M.D. Anderson Cancer Center
NCT04280081 ACTIVE NOT RECRUITING A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Eli Lilly and Company
NCT06961084 RECRUITING Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
Thomas Hope
NCT05786924 RECRUITING Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Institut de Recherches Internationales Servier
NCT05852223 RECRUITING Pembrolizumab in High-risk Thyroid Cancer
Istituti Clinici Scientifici Maugeri SpA
NCT05119296 ACTIVE NOT RECRUITING Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
NCT03157128 ACTIVE NOT RECRUITING A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Eli Lilly and Company
NCT01709292 ACTIVE NOT RECRUITING Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
NCT07470489 NOT YET RECRUITING Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
NCT06458036 RECRUITING Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Children's Hospital of Philadelphia
NCT07521670 NOT YET RECRUITING Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
National Cancer Centre, Singapore
NCT05696548 ACTIVE NOT RECRUITING Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
National Cancer Center Hospital East
NCT06007924 RECRUITING A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT07092514 RECRUITING Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Washington University School of Medicine
NCT03360890 ACTIVE NOT RECRUITING Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
University of Chicago
NCT02568267 ACTIVE NOT RECRUITING Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT07453225 NOT YET RECRUITING Empirical Radioactive Iodine Therapy in DTC
Assiut University
NCT04321954 ACTIVE NOT RECRUITING Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Massachusetts Eye and Ear Infirmary
NCT07193186 NOT YET RECRUITING Anlotinib and Benmelstobart in DTC
Fudan University
NCT07433283 RECRUITING Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
NCT02143726 ACTIVE NOT RECRUITING Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Alliance for Clinical Trials in Oncology
NCT03899792 ACTIVE NOT RECRUITING A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Eli Lilly and Company
NCT07235566 RECRUITING MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC
Fudan University
NCT05783323 RECRUITING Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Children's Hospital of Philadelphia
NCT04623801 ACTIVE NOT RECRUITING Laser Ablation of Papillary Thyroid Microcarcinoma
Memorial Sloan Kettering Cancer Center
NCT04544111 ACTIVE NOT RECRUITING PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT02628067 ACTIVE NOT RECRUITING Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Merck Sharp & Dohme LLC
NCT02657551 ACTIVE NOT RECRUITING A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Dana-Farber Cancer Institute
NCT06374602 RECRUITING Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia
NCT06359847 RECRUITING Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Beijing Scitech-Mq Pharmaceuticals Limited
NCT05864144 ACTIVE NOT RECRUITING A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NCT06970353 RECRUITING Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Fudan University
NCT03099356 RECRUITING Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
University of Michigan Rogel Cancer Center
NCT06923826 RECRUITING Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
National University Hospital, Singapore
NCT01141309 ACTIVE NOT RECRUITING Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT04560127 ACTIVE NOT RECRUITING Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
NCT04238624 ACTIVE NOT RECRUITING Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT03175224 RECRUITING APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics Inc.
NCT05275374 NOT YET RECRUITING XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
Xynomic Pharmaceuticals, Inc.
NCT04802876 ACTIVE NOT RECRUITING Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
SOLTI Breast Cancer Research Group
NCT06848920 NOT YET RECRUITING Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma
Zhejiang University
NCT06787911 RECRUITING Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
Yu Wang
NCT05668962 RECRUITING Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
NCT06713057 NOT YET RECRUITING Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
West China Hospital
NCT05007093 ACTIVE NOT RECRUITING Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
Yansong Lin
NCT06235216 RECRUITING Sacituzumab govitEcan in THYroid Cancers
Grupo Espanol de Tumores Neuroendocrinos
NCT05620134 ACTIVE NOT RECRUITING Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
NCT06362694 RECRUITING Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Saint Petersburg State University, Russia
NCT06121271 NOT YET RECRUITING Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
University College, London
NCT06087068 RECRUITING Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06079333 RECRUITING NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
Leiden University Medical Center
NCT05989425 RECRUITING Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Fudan University
NCT05660954 COMPLETED Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
Grupo Espanol de Tumores Neuroendocrinos
NCT03244956 COMPLETED Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
Gustave Roussy, Cancer Campus, Grand Paris
NCT03753919 TERMINATED Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
Grupo Espanol de Tumores Neuroendocrinos
NCT05745363 COMPLETED Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT04136912 TERMINATED 3-D Super Resolution Ultrasound Microvascular Imaging
UNC Lineberger Comprehensive Cancer Center
NCT04985604 TERMINATED Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT01723202 COMPLETED Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Bhavana Konda
NCT04521348 COMPLETED Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
Fudan University
NCT04400474 COMPLETED Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Grupo Espanol de Tumores Neuroendocrinos
NCT03246958 COMPLETED Nivolumab Plus Ipilimumab in Thyroid Cancer
Dana-Farber Cancer Institute
NCT05253053 COMPLETED To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT04552769 COMPLETED Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
NCT03037385 COMPLETED Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Hoffmann-La Roche
NCT04579757 TERMINATED Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
NCT05175404 COMPLETED Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers
University Hospital, Ghent
NCT02152137 COMPLETED Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Alliance for Clinical Trials in Oncology
NCT04731467 COMPLETED A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Famewave Ltd.
NCT05500508 TERMINATED Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
NCT03127098 TERMINATED QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
NCT02383927 COMPLETED Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Kura Oncology, Inc.
NCT01856920 COMPLETED QUILT-3.006 for Recurrent Medullary Thyroid Cancer
NantCell, Inc.
NCT04782856 COMPLETED Energy Metabolism in Thyroidectomized Patients
Virginia Commonwealth University
NCT04161391 TERMINATED Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
NCT04742959 COMPLETED Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
NCT03565536 COMPLETED Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Fujian Medical University
NCT04137185 COMPLETED Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT04327999 TERMINATED Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
Vanderbilt-Ingram Cancer Center
NCT02244463 COMPLETED A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Dana-Farber Cancer Institute
NCT04644315 TERMINATED A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Hoffmann-La Roche
NCT02988817 COMPLETED Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Genmab
NCT02947035 COMPLETED Molecular Testing to Direct Extent of Initial Thyroid Surgery
University of Pittsburgh
NCT02432274 COMPLETED Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Eisai Limited
NCT01882816 COMPLETED Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT02408887 TERMINATED Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer
National Cancer Institute (NCI)
NCT02404441 COMPLETED Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Novartis Pharmaceuticals
NCT01730638 COMPLETED ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
Nantes University Hospital
NCT02688608 COMPLETED Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Saad A Khan
NCT02731352 COMPLETED Study of Apatinib in Patients With Differentiated Thyroid Cancer
Peking Union Medical College Hospital
NCT02702388 COMPLETED A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Eisai Inc.
NCT00936858 COMPLETED RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Dana-Farber Cancer Institute
NCT03139747 SUSPENDED UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Thomas Jefferson University
NCT03838692 WITHDRAWN Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Antonio Fojo
NCT03131206 TERMINATED A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Dana-Farber Cancer Institute
NCT03630120 TERMINATED Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT01270321 COMPLETED Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Emory University
NCT03072160 COMPLETED Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
National Cancer Institute (NCI)
NCT02138214 COMPLETED Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer
University of Wisconsin, Madison
NCT02709889 TERMINATED Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
NCT00603941 TERMINATED A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
NCT01728623 COMPLETED A Study of E7080 in Subjects With Advanced Thyroid Cancer
Eisai Co., Ltd.
NCT00668811 COMPLETED Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Medstar Health Research Institute
NCT01788982 COMPLETED Nintedanib(BIBF1120) in Thyroid Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT02726503 COMPLETED Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
NCT00784303 COMPLETED Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Eisai Inc.
NCT02614495 COMPLETED Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
Hutchison Medipharma Limited
NCT02390739 WITHDRAWN Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
National Cancer Institute (NCI)
NCT00582712 TERMINATED An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
University of Wisconsin, Madison
NCT01013597 COMPLETED Trial of LBH589 in Metastatic Thyroid Cancer
University of Wisconsin, Madison
NCT02084732 COMPLETED Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Instituto Nacional de Cancerologia, Columbia
NCT02657369 TERMINATED A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Eisai Inc.
NCT01813136 COMPLETED Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Centre Leon Berard
NCT02289144 WITHDRAWN Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
University of Texas Southwestern Medical Center
NCT02390934 COMPLETED Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
Gustave Roussy, Cancer Campus, Grand Paris
NCT02472080 TERMINATED Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study
Assistance Publique - Hôpitaux de Paris
NCT02870569 COMPLETED Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT03002623 TERMINATED CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Cancer Institute (NCI)
NCT00923247 TERMINATED A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
National Cancer Institute (NCI)
NCT01229865 COMPLETED Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Vascular Biogenics Ltd. operating as VBL Therapeutics
NCT00896454 COMPLETED Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
NCT00804830 TERMINATED Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Region Skane
NCT01025453 COMPLETED Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT01502410 COMPLETED Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
National Cancer Institute (NCI)
NCT02114658 COMPLETED Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Bayer
NCT01240590 COMPLETED A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
National Cancer Institute (NCI)
NCT01661179 COMPLETED Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Genzyme, a Sanofi Company
NCT02515084 COMPLETED Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma
Centre Henri Becquerel
NCT01625520 COMPLETED SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Federico II University
NCT01994200 WITHDRAWN Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
Jewish General Hospital
NCT01173289 COMPLETED Study of External Beam Radiotherapy to Thyroid Carcinoma
National Cancer Center, Korea
NCT01964144 COMPLETED An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer
Yonsei University
NCT01736878 WITHDRAWN Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
Eanm Research Ltd
